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Abstract
Background: Epithelial to mesenchymal transition (EMT) is a well-characterized process of cell plasticity that may
involve metabolic rewiring. In cancer, EMT is associated with malignant progression, tumor heterogeneity, and
therapy resistance. In this study, we investigated the role of succinate dehydrogenase (SDH) as a potential key
regulator of EMT.
Methods: Associations between SDH subunits and EMT were explored in gene expression data from breast cancer
patient cohorts, followed by in-depth studies of SDH suppression as a potential mediator of EMT in cultured cells.
Results: We found an overall inverse association between EMT and the SDH subunit C (SDHC) when analyzing
gene expression in breast tumors. This was particularly evident in carcinomas of basal-like molecular subtype
compared to non-basal-like tumors, and a low SDHC expression level tended to have a prognostic impact in those
patients. Studies in cultured cells revealed that EMT was induced by SDH inhibition through SDHC CRISPR/Cas9
knockdown or by the enzymatic inhibitor malonate. Conversely, overexpression of EMT-promoting transcription
factors TWIST and SNAI2 caused decreased levels of SDHB and C and reduced rates of SDH-linked mitochondrial
respiration. Cells overexpressing TWIST had reduced mitochondrial mass, and the organelles were thinner and more
fragmented compared to controls.
Conclusions: Our findings suggest that downregulation of SDHC promotes EMT and that this is accompanied by
structural remodeling of the mitochondrial organelles. This may confer survival benefits upon exposure to hostile
microenvironment including oxidative stress and hypoxia during cancer progression.
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Introduction
Epithelial to mesenchymal transition (EMT) provides a
useful mechanistic framework for studying the regula-
tion and dynamics of cell fate transitions (i.e., cell plasti-
city) central to developmental and cancer cell biology
[1–3]. Events involving downregulation or dysfunction
of mitochondrial enzymes have been linked to EMT, but
the potential role of mitochondrial remodeling as part of
the EMT program has not yet been evaluated through
systematic studies of mitochondrial physiology [4].
EMT is a reversible transdifferentiation program
whereby epithelial cells convert into migratory mesenchy-
mal cells with enhanced cell survival attributes [1, 2].
EMT is recognized by a loss of epithelial markers such as
cytokeratins and E-cadherin, followed by a concomitant
increase in mesenchymal markers such as N-cadherin and
vimentin [5]. In cancer development, this is associated
with therapy resistance and poor clinical outcome [6]. The
cellular processes of EMT are orchestrated by several key
transcription factors (e.g., TWIST, SNAI1, SNAI2, ZEB1/
2) that act in concert with epigenetic mechanisms and
post-translational protein modifications to coordinate the
cellular alterations [1]. Application of gene expression sig-
natures combining multiple EMT-linked genes has proven
useful to evaluate EMT as a contributing factor in tumor
development in human cancers [7].
Cellular metabolism provides the energy and building
blocks required for cell function and growth and is regu-
lated in close relation to changes in the physiological
state of the cell and in the microenvironment [8]. To
this end, mitochondrial reprogramming has been shown
to be of significance in oncogenic events [9, 10]. Several
oncometabolites recognized as drivers of tumor develop-
ment and progression have been identified, including fu-
marate, D-2-hydroxyglutarate (D-2HG), and succinate
[11]. Such metabolites have been found to have causative
influence in cancers with genetic deficiencies in associ-
ated enzymes, including fumarate hydratase (FH) [12],
isocitrate dehydrogenase 1 (IDH1) [8], and succinate
dehydrogenase (SDH) [13]. Mutations (germline) in
SDH subunits have been linked to familial paraganglioma
syndromes, pheochromocytomas (PGL/PCC), renal cell
carcinomas (RCC), and gastrointestinal stromal tumors
(GISTs) [14], both as predisposing and prognostic factors
[13]. Thus, in PGL/PCC, GIST, and RCC, SDH is classi-
fied as a tumor suppressor [13, 15–18].
The SDH complex, also referred to as respiratory com-
plex II in the mitochondrial electron transport chain, is
composed of four subunits (SDHA, SDHB, SDHC, and
SDHD). It has a central role in energy metabolism, as it
directly links the tricarboxylic acid cycle (TCA-cycle) to
the respiratory machinery [19]. SDHA and SDHB are
hydrophilic subunits and form the catalytic unit of the
complex, whereas SDHC and SDHD represent the
hydrophobic membrane-bound part of the complex.
SDH genes can act as classic tumor suppressor genes, as
the mutated alleles often are inherited in a heterozygous
manner, and the respective wild-type allele is lost in tu-
mors [9]. Mutations in or downregulation of the SDHB
subunit have previously been associated with
TGFβ-induced EMT in cancer cells [20–22]. In a previ-
ous study investigating breast cancer, the protein expres-
sion level of SDHA and B was lost in 3% of the samples
[23]. Such effects may indicate that metabolic rewiring
could be a facilitating feature for cell plasticity, as it also
has been linked to cell state transitions such as differen-
tiation, senescence, and oncogenic transformation [4,
24–27]. In summary, there are several observations sup-
porting that genetic defects in mitochondrial enzymes
may affect features of EMT [4, 13, 28, 29]. However, the
potential role of metabolic rewiring as a more general
driving force of cellular plasticity in human tumors re-
mains poorly explored.
In this study, we present gene expression analysis of
human breast cancer samples, correlating the level of
SDH subunits to the levels of EMT-related genes. We
show that reduced expression of SDHC was particularly
associated with EMT in the breast cancer cohorts of this
study, especially the ductal- and basal-like subgroups. In
subsequent cell studies, we found a bilateral causative
relationship between SDH attenuation and EMT induc-
tion, which involved significant changes in mitochon-
drial morphofunctional properties.
Methods
Gene expression analysis of human breast cancer samples
We investigated the association between EMT and SDH
genes in a breast cancer patient cohort obtained from
the Haukeland University Hospital (n = 204) [30], as
well as an Affymetrix breast cancer meta-cohort (n =
3992) [7]. In this study, we used two distinct signatures,
one generic comprising 315 genes related to EMT in
various tissues (EMT315 signature) [7], and the other
consisting of 8 genes of particular relevance for EMT in
breast cancer (EMT8 signature). The EMT8 signature
was designed based on a previously described 5-gene
signature (CDH1, CTNNB1, CTNNA2, CDH2, CDH3)
[31], which we extended with KRT19, an established
marker for breast cancer cells, and SNAI2 and TWIST
due to their role as determinants of EMT in breast can-
cer metastasis and invasion. The correlation between
the two different EMT signature scores was strong in
our study cohorts (for the meta-cohort Rho = 0.674, p <
0.0001 and for the n = 204 cohort Rho = 0.6651, p <
0.0001). Further details about the gene expression analysis
(GEA) are provided in Additional file 1: Supplemental
methods.
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Cell models
The breast epithelial cell line MCF10A and the breast can-
cer cell line MCF7 (both from ATCC, Manassas, VA) were
cultured according to conventional procedures (further
described in Additional file 1: Supplemental methods).
Overexpression of EMT-linked transcription factors
Stable modified MCF10A subclones overexpressing TWIST
or SNAI2 were established by retroviral transduction, as de-
scribed previously [32], and termed MCF10A/TWIST and
MCF10/SNAI2, respectively. The plasmid constructs used
are previously described [33]. The cells were exposed to the
virus for 2 × 8 h, interrupted by 8-h incubation in standard
medium. In addition, a control subclone was prepared by
insertion of the empty vector, which contained the
gene for GFP (MCF10A/GFP). Transduction positive
cells were sorted by FACS using the GFP marker.
CRISPR/Cas9 in vitro gene editing of SDHC and SDHD
MCF7 cells with heterozygous knockdown of SDHC
(MCF7 SDHC+/−) was obtained by introducing a frameshift
deletion within the coding region (exon 3) of the gene.
Twenty nucleotides gRNA targeting SDHC were designed
(ATAGTAATGTGGGGAGACAG) using the Benchling
online tool (www.benchling.com). The oligo-nucleotide
sequences were synthesized with the suitable overhangs
for plasmid insertion (CACCGATAGTAATGTGGGG
AGACAG and AAACCTGTCTCCCCACATTACTATC),
before insertion into the pX458SpCas9 plasmid (Addgene,
Waltertown, MA, USA), which had been modified to
increase the fidelity of Cas9, (according to [34], kindly
provided by Ole M. Seternes). The primers were
phosphorylated and annealed using T4 PNK (NEB),
followed by digestion/ligation into the plasmid, utiliz-
ing Golden Gate reaction using BbsI enzyme (NEB)
and T7 ligase (NEB). The gRNA inserts were further
sequenced to confirm the correct insertion using the
U6 primer (GATACAAGGCTGTTAGAGAGATAATT).
The cells were transfected with the gRNA containing con-
struct using Lipofectamine LTX (Invitrogen, Carlsbad,
CA, USA) for 5 days. Subsequently, cells were sorted into
a 96-well plate (one cell per well) based on GFP expres-
sion from the vector, using Sony SH800S cell sorter. Upon
colony formation in the wells, DNA was purified from
each clonal colony and the targeted region was amplified
by PCR and sequenced using forward primer CTCG
GCCTCCCAAAGAGCTGAGATTA and reverse primer
CTCATCTACATAGCAGTATTTTGGTTGAGTAA. The
PCR products revealing deletion(s) were further inserted
into (vector) by TOPO TA cloning and subject to
re-sequencing, in order to confirm that mutation was
introduced.
mRNA expression analysis by quantitative polymerase
chain reaction
Total RNA was isolated from cell pellets using the
RNeasy MINI KIT (74104, Qiagen, Venlo, Netherlands).
cDNA was synthesized using the High-Capacity cDNA
Reverse Transcription Kit (4368813, Thermo Fisher
Scientific, Waltham, MA) and Biorad MJ Mini Thermal
Cycler (Hercules, CA, USA). The quantitative polymerase
chain reaction (qPCR) was performed using the Light
Cycler 480 system (Roche, Basel, Germany) and the Light
Cycler 480 Probes Master reaction mix
(Cat# 04887301001, Roche). The gene-specific probes
used are listed in Additional file 2: Table S3. The ΔΔct
method was used for calculating fold change in gene ex-
pression relative to the control sample.
Mitochondrial DNA quantification
Total DNA was purified from cell pellets using the DNeasy
blood and tissue kit from Qiagen (69504, DNeasy Blood
and tissue kit, Qiagen). Taqman probe/primer mixtures for
mitochondrial NADH dehydrogenase 1 (mitochondrial
DNA (mtDNA) gene; Hs02596873_s1 MTND1) and
eukaryotic 18 s rRNA (nuclear gene; 4333760F, Applied
Biosystems, CA, USA) were used. Following quantification
by qPCR, the amount of mtDNA relative to nuclear DNA
was calculated as the ratio between the levels of MTND1
and 18 s RNA using the ΔΔct method [32].
Western blot analysis
Cells were scraped and lysed in RIPA lysis buffer
(sc24948, Santa Cruz Biotechnology, Dallas, TX). Protein
concentration of the lysed samples were measured by
the Pierce® BCA Protein Assay Kit (Thermo Fisher Sci-
entific). Electrophoresis was done using premade Biorad
stain-free gels (Biorad Mini-PROTEAN 3 Cell), and the
protein was transferred to polyvinylidene fluoride PVDF
membranes (GE Healthcare, Little Chalfont, U.K) by
BioradTurbo Transfer System. Before stained with respect-
ive antibodies (Additional file 2: Table S3), total protein was
assessed by imaging on ChemiDocTM XRS+ with Image
Lab Software (Biorad).
Spheroid and scratch-wound assays
For measurement of spheroid formation capacity,
Geltrex LDEV-free (Thermo Fisher Scientific) was used
as a gel matrix. In a 12-well plate, 350 μl/well of Geltrex
was casted and solidified at 37 °C for 30 min. Twenty-
five thousand cells were suspended in 500 μl of assay
medium (2% of geltrex in medium) and added to the
solidified matrix. Cells were incubated at 37 °C and cell
growth and colonies were observed for 3–7 days. For ana-
lysis of spheroid stability and growth, centrifugation-assisted
spheroid formation was performed by transferring the cells
(5000 cells/well) to a 96-well u-bottom ultralow attachment
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plate (Corning, Thermo Fisher Scientific), followed by cen-
trifugation for 15min at 300 rcf (room temperature). The
Incucyte ZOOM 2016B (EssenBioscience Ltd., UK) was
used for time-lapse imaging of the spheroids and for
scratch-wound assay. For MCF7 spheroids, the area was
calculated from the average radius retrieved from measuring
two perpendicular diameters (Image Pro Software ver-
sion 7.0, Media Cybernetics, Inc., Washington, USA).
Ten spheroids were measured in each group. For the
scratch-wound assay, cells were plated at 45 k cells/
well (IncuCyte ImageLock Plates cat #4397) for an
optimal 80–90% confluency and incubated over-night.
Just prior to the time-lapse imaging sequence, scratch
wound was made to the monolayer using the wound
maker (IncuCyte Cell Migration Kit, cat# 4493). The
cultures were imaged using the Incucyte ZOOM
2016B or by phase contrast microscopy of monolayers
fixed in methanol with crystal violet. The percent
wound closing after 24 h relative to start was mea-
sured using the IncuCyte scratch-wound cell migra-
tion software module (Cat# 9600-0012), or by phase
contrast microscopy with ocular micrometer, measur-
ing the gap distance at a fixed location.
Mitochondrial respiration
Oxygen consumption rate (OCR) was measured using
the Seahorse XFe96 Analyzer (Agilent, Santa Clara, CA),
according to the manufacturer’s protocols and previous
descriptions [32, 35]. All materials were from Sigma-Al-
drich (St. Louis, MO) unless otherwise stated. For ana-
lysis of SDH-linked activity, the cells were permeabilized
to facilitate cellular uptake of succinate and ADP, by
adding the Seahorse XF plasma membrane permeabili-
zer (PMP) (Agilent), as indicated. The concentration of
PMP and metabolic modulators (uncoupler, inhibitors)
were optimized for each cell type. The data were nor-
malized to cell number using Hoechst 33342 (Thermo
Fisher Scientific) or protein content (Pierce® BCA Pro-
tein Assay Kit, Thermo Fisher Scientific). Further de-
tails are provided in Additional file 1: Supplemental
methods.
Flow cytometric G0–G1 separation by Pyronin Y and
Hoechst 33258 staining
Cell pellets (1 mill cells) were treated with 50 μg/ml
Hoechst 33342 (Thermo Fisher Scientific) for 1 h in 37 °C.
After washing, the cells were stained with 1 μg/ml Pyronin
Y (Sigma-Aldrich) for 30min in 37 °C. Cells were washed
and filtered before flow cytometric analysis. Pyronin Y was
detected at ca 570 nM and Hoechst was detected at 405 nm
at the Fortessa LSR (BD Biosciences, San Jose, CA). Ana-
lysis was performed in FlowJo software.
Immunocytochemistry
Cells were plated on cover slips in 24-well culture plates
(10,000 cells/well) and left until they reached 70% con-
fluency. The cells were then fixed in 3.7% PFA,
permeabilized with TBS-T, and stained with primary
antibodies for E-cadherin (cat # 14472, Cell Signaling,
Leiden, Netherlands) and vimentin (AB92547, Abcam,
UK), and diluted 1:100 in TBS-T with 0.5% BSA. Alexa
594 anti-mouse and Alexa-647 anti-rabbit were used as
secondary antibodies. The cells were thereafter stained
with 1:40 Phalloidin AF555 (a34055, Thermo Fisher Scien-
tific) according to the manufacturer’s instruction, before
mounting with Prolong Dimond with Dapi (Thermo
Fisher Scientific). Images were acquired on a Leica TC2
SP8 STED 3X with HC PL APO CS2 lasers using the
100 × 1.4 NA oil objective.
Confocal microscopy and three-dimensional image
analysis of mitochondria
Mitochondria were stained using immunocytochemistry
(ICC) (as described above) with primary antibodies against
TOM20 (FL145 Santa Cruz Biotech, Dallas, Texas; 1:100);
and ATPB (AB5452 Abcam, Cambridge, UK; 1:500). Im-
aging was performed by confocal microscopy (Leica TCS
S5 microscope, Leica microsystems, Wetzlar, Germany).
Image processing, three-dimensional (3D)-modeling and
quantitative analysis of mitochondrial structures were per-
formed using the Image-Pro Plus software (version 7.0)
(Media Cybernetics), as described previously [32, 36]. Fur-
ther details are provided in Additional file 1: Supplemental
methods.
Results
Association between EMT and reduced SDHC expression
in human breast cancer
We investigated the association between EMT and the
different SDH subunits in human breast tumors, based
on gene expression in a patient cohort obtained from
the Haukeland University Hospital (n = 204) [30] and an
Affymetrix breast cancer meta-cohort (n = 3992) [7].
Using both a breast cancer-directed 8-gene signature
(EMT8) and a generic 315-gene signature (EMT315),
EMT was found to be particularly associated with reduced
SDHC expression in the n = 204 cohort, with a Rho value
of − 0.422 (p < 0.0001) using the EMT8 signature (Fig. 1a)
and Rho value of − 0.55 (p < 0.0001) using the EMT315
signature (Fig. 1b). SDHA and SDHB expression were not
associated with EMT, whereas SDHD demonstrated a
positive relationship upon using the EMT315 signature
(Rho = 0.303, p < 0.0001) (Fig. 1b). We also investigated if
the expression of the SDH subunits was specifically asso-
ciated with the central EMT-linked transcription factors
TWIST and SNAI2. The analysis indicated that SDHC
was inversely correlated to both TWIST1 (Rho = − 0.337,
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p < 0.0001) (Fig. 1c) and SNAI2 (Rho = 0.27, p < 0.0001),
whereas SDHD showed a positive correlation to SNAI2
(Rho = 0.328, p < 0.0001) (Additional file 2: Figure S1A).
Neither SDHA, SDHB, nor SDHD showed associations
to TWIST1. To verify these results, we applied the
EMT315 signature on the Affymetrix breast cancer patient
meta-cohort (n = 3992). In concordance with our previous
observations in the n = 204 cohort, there was an inverse as-
sociation between EMT and SDHC (Rho = − 0.283, p <
0.0001) (Fig. 1d). In support, we found a similar inverse
correlation between EMT315 and SDHC gene expression
in a breast invasive carcinoma cohort (Rho = − 0.337, p <
0.0001) as well as in breast cancer cell lines (Rho = − 0.517,
p < 0.0001) in TCGA RNA-seq data (Additional file 2: Table
S1). Correlation analysis between the individual SDH sub-
units in the n = 204 cohort generally returned statistically
significant associations between subunit pairs, although
with relatively low Rho-value (Additional file 2: Figure S1B).
This suggests some level of co-regulation of the expression
of the individual subunits, as would be expected since the
resulting proteins belong to the same enzyme complex. In
summary, these data linked EMT to SDHC suppression in
breast cancer and suggested that TWIST and SNAI2, two
of the master promoters of EMT, could be involved.
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Fig. 1 Association between SDH and EMT in gene expression data from breast cancer patient cohorts. Gene expression (mRNA) correlation
analysis (Spearman) between SDH subunits and EMT signature in datasets from breast cancer patients. a Breast cancer patient cohort (n = 204),
using the EMT8 signature (8 genes). b Breast cancer patient cohort (n = 204), using the EMT315 signature (315 genes). c Breast cancer patient
cohort (n = 204), correlation with TWIST1 expression. d Affymetrix breast cancer patient meta cohort (n = 3992), relative to the EMT315 signature.
The gene expression data are displayed with relative arbitrary units
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Low SDHC expression is associated with a poor prognosis
in basal-like tumors
Next, we investigated the relationship between EMT and
SDHC when the cohort was divided into molecular sub-
groups. When we looked at the relative levels of SDHC
mRNA, we found no difference between the n = 204
cohort tumors classified as either ER+ and ER−, or
as ductal and lobular carcinoma (Fig. 2a). Note-
worthy, we found significantly lower SDHC expres-
sion in basal-like compared to non-basal tumors,
and this coincided with significantly higher EMT8
score (Fig. 2b). A higher EMT8 score was seen in
ER− tumors compared to ER+, but there was no difference
between the histological ductal and lobular types. This is in
agreement with the known phenotypic differences between
basal-like and other breast tumor subtypes. The higher
EMT status in ER− vs ER+ tumors and basal-like vs
non-basal-like tumors were further supported in the Affy-
metrix meta-cohort, using either of the EMT signatures
(Fig. 2d); however, the overall SDHC expression did not dif-
fer between the subgroups of this cohort (Fig. 2c). Histo-
logical subclassification (i.e., ductal vs lobular carcinoma)
was not available for the Affymetrix meta-cohort. Correl-
ation analysis was performed to evaluate the relationship
between SDHC expression and EMT status within each
breast cancer subgroup. The SDHC mRNA level was in-
versely associated with the EMT8 score in each subgroup
of the n = 204 cohort (with Rho between − 0.431 and −
0.373), except for lobular breast cancer (Fig. 2e). In support,
we found an inverse association between SDHC expression
and EMT315 score in the subgroups of the Affymetrix
meta-cohort, somehow stronger in basal-like tumors
(Rho = − 0.361, p < 0.0001) compared to the non-basal-like
tumors (with Rho between − 0.292 and − 0.256) (Fig. 2f).
Interestingly, low SDHC expression tended to be associ-
ated with poorer survival in patients with basal-like tu-
mors, compared to patients with a high level of SDHC
(chi-square = 2.821, p = 0.093) (Fig. 2g). This trend was
not seen in patients with non-basal like tumors.
SDH attenuation by SDHC knockdown induces EMT in
breast cancer cells (MCF7)
The initial gene expression analysis in human breast
tumors and cell lines convincingly suggested that
EMT is associated with reduced SDHC expression. To
explore the impact of reduced SDHC expression on
EMT-related features, we knocked down this gene in
MCF7 breast cancer cells, using the CRISPR/Cas9
system. Successful heterozygous CRISPR/Cas9 editing
of SDHC (MCF7 SDHC+/−) was confirmed by sequencing
(Additional file 2: Figure S2), and the resulting reduction
in SDHC mRNA and protein was verified (Fig. 3a and b).
Immunostaining and fluorescence microscopy indicated
reduced protein levels of E-cadherin in MCF7 SDHC+/−
compared to MCF7 SDHC+/+cells, and F-actin staining
with phalloidin revealed a concordant transition from
epithelial to mesenchymal-like cell morphology (Fig. 3c).
The knockdown of SDHC was also accompanied by
marker expression consistent with induction of EMT,
i.e, E-cadherin (CDH1) was downregulated and vimentin
(VIM), SNAI2, TWIST, and AXL [33] were upregulated
(Fig. 3d). The level of N-cadherin (CDH2) mRNA was un-
detectable in both MCF7 SDHC+/+ and MCF7 SDHC+/−
cells. Consistent alterations in morphological phenotype
were also visualized by contrast enhancement microscopy
during the course of these experiments. The MCF7
SDHC+/− cells demonstrated reduced capacity to form
spheroids in plates with low surface adherence when com-
pared to MCF7 SDHC+/+ cells (Fig. 3e). Further, following
centrifugation-aided spheroid formation, the MCF7
SDHC+/− spheroids decreased in size, whereas the MCF7
SDHC+/+ spheroids grew significantly (Fig. 3f and g). This
reduced growth and stability of the multicellular spheroids
are consistent with a mesenchymal phenotype, as is the
loss of cell-cell adherence observed near the periphery of
the MCF7 SDHC+/− spheroids.
In order to study effects of SDHC knockdown on mito-
chondrial respiration, we measured the oxygen consump-
tion rate (OCR) under normal cell culture conditions
(DMEM medium) with glucose, pyruvate, and glutamine
as the major fuels and then under conditions specifically
composed to access changes in SDH function. In the pres-
ence of glucose, pyruvate, and glutamine as the major oxi-
dative substrates, the MCF7 SDHC+/− cells demonstrated
normal basal respiratory rate; however, they had signifi-
cantly reduced uncoupled respiratory capacity after
addition of oligomycin and CCCP (Fig. 3h). To investigate
succinate-dependent mitochondrial respiration, OCR was
measured in permeabilized cells, in the presence of the
complex I inhibitor, rotenone, and with succinate as the
only oxidation fuel (Fig. 3i). After adding succinate, the
OCR increased immediately and continued to rise in the
MCF7 SDHC+/+ cultures. In contrast, succinate caused
only a transient OCR induction in the MCF7 SDHC+/−
cultures. Furthermore, while OCR increased after addition
of ADP in MCF7 SDHC+/+ cultures, there was no effect of
ADP for MCF7 SDHC+/−. The increased OCR after
addition of ADP, and the subsequent inhibition by the
ATP synthase inhibitor oligomycin, confirms that this
SDH-linked respiration was coupled to ATP production
through oxidative phosphorylation (OXHOS) in the
MCF7 SDHC+/+ cells. The absence of such ADP-linked ef-
fects in the MCF7 SDHC+/− cells indicates that these cells
were unable to utilize succinate to fuel ATP production.
In summary, the MCF7 SDHC+/− cells were incapable of
maintaining succinate-driven mitochondrial respiration
and OXPHOS under these conditions, consistent with an
attenuation of SDH activity.
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Further, properties of migration were investigated
in a scratch wound experiment, where we also in-
cluded MCF7 SDHD+/− cells (sequencing data in
Additional file 2: Figure S2B), as SDHD demon-
strated a different relationship with EMT compared
to SDHC in the previous tumor gene expression ana-
lysis. Similar to the control MCF7 SDHC/D+/+ cells (par-
ental), and in contrast to the mesenchymal-like MCF7
SDHC+/− cells, the MCF7 SDHD+/− cells had an epithelial
morphology (Fig. 3j). The scratch-wound study clearly
showed that MCF7 SDHC+/− cells had significantly higher
wound healing capacity compared to MCF7 SDHC/D+/+
and MCF7 SDHD+/− cells, as evident by a significantly
smaller gap distance 24 h after the wound was made
(Fig. 3k and l).
SDH enzyme inhibition triggers EMT
The results so far suggested that EMT is associated with
downregulation of SDH and that defective function of
this enzyme may be a causative factor for EMT in
tumors. To investigate if this link between EMT and
SDH has a general relevance also in non-tumorigenic
cells, we studied the effects of the competitive succinate
dehydrogenase enzymatic inhibitor malonate in the hu-
man mammary epithelial cell line MCF10A. Treatment
with malonate for 3 days significantly reduced basal
respiration and uncoupled respiratory capacity (Fig. 4a
and b). Further, malonate treatment was confirmed to
inhibit SDH by reducing SDH-linked respiration mea-
sured in permeabilized cells in the presence of succinate
and ADP (Fig. 4c and d). In both of these experiments,
the normal response to the addition of oligomycin, and
subsequently ADP or uncoupler, confirmed that the in-
tegrity of the OXPHOS system remained intact upon
malonate treatment. Importantly, the malonate treat-
ment caused increased expression of vimentin and
N-cadherin and reduced expression of E-cadherin, both
on the level of mRNA (Fig. 4e) and on protein (Fig. 4f ).
This typical marker profile of EMT was consistent with
the consequent change in cellular morphology (Fig. 4g).
These data support that inhibition of SDH enzyme ac-
tivity may constitute an inherent trigger of the EMT
program.
Overexpression of EMT-linked transcription factors leads
to attenuation of SDH
Gene expression analysis suggested that there is a
regulatory relationship between EMT-related genes
and SDH subunits, especially regarding SDHC, in the
breast cancer cohorts of this study. To determine if
EMT-linked transcription factors could be involved in
SDH downregulation, we overexpressed TWIST and
SNAI2 in MCF10A cells (MCF10A/TWIST and MCF10A/
SNAI2, respectively). Both the modified cell types presented
a switch from epithelial to mesenchymal phenotype, as seen
by confocal imaging showing characteristic changes in cell
morphology, remodeling of the cytoskeleton, increased level
of vimentin, and a reduced level of E-cadherin (Fig. 5a). In-
duction of EMT was further verified by increased expres-
sion levels of vimentin, N-cadherin, Axl, PRXX1, and
downregulated E-cadherin, as well as reduced cell prolifera-
tion (Additional file 2: Figure S3). In a centrifugation-aided
spheroid formation experiment, the parental MCF10A cells
formed dense spheroid structures, whereas the MCF10A/
TWIST and MCF10A/SNAI2 cells formed less compact
structures with loosened cell-cell contact, as expected upon
EMT (Fig. 5b). Moreover, a congruent reduction in total
RNA level was measured in MCF10A/TWISTcells (Fig. 5c),
reflecting a higher content of cells in the state of quiescence
due to EMT. Following the verification of EMT in the
modified cells, we investigated the effects on SDH. Reduced
protein expression of both SDHB and SDHC was detected
in the MCF10A/TWIST cells (Fig. 5d). Analysis of oxygen
consumption demonstrated that the rates of mitochondrial
respiration were lower in MCF10A/TWIST and MCF10A/
SNAI2 cells, compared to controls (Fig. 5e–g). The lower
rates of leak respiration in the overexpressing cells contra-
dict the possibility that the integrity of mitochondrial inner
membrane could be compromised, as this would lead to in-
creased leak respiration due to uncoupling effects. Rather,
the lower leak respiration may be explained by a general de-
crease in mitochondrial respiration. Similar to the previous
studies, we then measured SDH-linked respiration in
permeabilized cells, in the presence of rotenone, succinate,
and ADP (Fig. 5h and i). We found that the activity of SDH
was significantly reduced in the MCF10A/TWIST cells,
compared to control. Also in these cells, mitochondrial in-
tegrity remained intact despite the loss of SDH activity,
(See figure on previous page.)Fig. 2 SDHC gene expression in subgroups of breast cancer. The two cohorts included in the study was
subdivided based on molecular characteristics such as estrogen receptor positive and negative (ER+ and ER−) and basal- and non-
basal phenotype. Claudin-low and triple negative subgroups were included in the basal category. In addition, the breast cancer
patient cohort (n = 204) was subgrouped based on histology, i.e., into ducal and lobular characteristics. a mRNA expression of SDHC
and b EMT8 signature were assessed for the distinct subgroups in the n = 204 cohort. c mRNA expression of SDHC and d EMT8 and
EMT315 signatures were determined for the subgroups in the n = 3992 Affymetrix meta cohort. e Spearman correlation analysis for
SDHC expression relative to EMT8 signature for subgroups of the breast cancer cohort (n = 204) and f the Affymetrix meta cohort. g
Kaplan-Meier survival plots for basal- (n = 42) and non-basal-like (n = 161) breast carcinoma of the breast cancer cohort. The gene
expression data are displayed with relative arbitrary units
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Fig. 3 (See legend on next page.)
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(See figure on previous page.)
Fig. 3 Induction of EMT in MCF7 upon SDHC knockdown. Parental MCF7 cells (MCF7 SDHC+/+) were modified by CRISPR/Cas9 editing to knock
down the expression of SDHC (MCF7 SDHC+/−). a SDHA-D mRNA was analyzed by qPCR. b SDHC protein expression was analyzed by western
blotting. c Confocal microscopy was performed to evaluate E-cad (immuno-stained, green) expression level and cell morphology (F-actin stained
by phalloidin, red). dmRNA expression of the EMT markers E-cad (CDH1), vimentin (VIM), TWIST1, SNAI2, and Axl. e Spheroid formation (anchorage-
independent) was evaluated after seeding the cells in wells with low surface adherence. f Spheroid growth and stability was assessed after centrifugation-
aided spheroid formation. The spheroid size was measured after 48 h in culture. g The diagram shows statistical data from the experiment described in (f).
h Mitochondrial respiratory rates were measured in MCF7 SDHC+/+ and MCF7 SDHC+/− cultures, with glucose, pyruvate, and glutamine provided as the
major fuels. Oxygen consumption rate (OCR) was monitored upon sequential additions of oligomycin (O, 3 μM), CCCP (C, 0.75 μM), rotenone (R, 1 μM), and
antimycin A (A, 1 μM) as indicated, to assess specific properties of mitochondrial respiration. i For measurement of SDH-dependent mitochondrial
respiration, the cells were permeabilized (with PMP) and rotenone was added prior to analysis in restricted assay medium (MAS). Succinate (SUCC, 10mM),
ADP (4mM), oligomycin (OLIGO, 3 μM), and antimycin A (AMA, 1 μM) were added sequentially as indicated. j Fluorescence microscopy was performed to
compare cell morphology (F-actin stained by phalloidin, white) in MCF7 SDHD/C+/+, MCF7 SDHC+/−, and MCF7 SDHD
+/− cultures. k Scratch-wound assay
comparing MCF7 SDHD/C+/+, MCF7 SDHC+/−, and MCF7 SDHD
+/− cells. The images were taken 24 h after the scratch was made. l In the experiment
described in (k), we measured scratch size as gap distance (d) at a fixed position, after 24 h, and calculated the results relative to the initial scratch size. Each
dot represents separate wells. Data are shown as mean ± SD for (a), (d), (g), and (l) and mean ± SEM for (h) and (i). Student’s t test was used for statistical
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Fig. 4 SDH enzyme inhibition causes induction of EMT. We investigated if SDH enzyme inhibition causes induction of EMT by treating MCF10A
cells with the SDH inhibitor malonate (25 mM) for 3 days. a Conventional analysis of mitochondrial respiratory function by measuring oxygen
consumption rate (OCR) in DMEM medium in malonate treated MCF10A cells. b The diagram shows statistical data from the experiment
described in (a). c SDH-linked respiration was assessed with succinate (Succ) as the only provided substrate, following the addition of cell
permeabilizing agent (PMP) and ADP. Oligomycin (Oligo) and antimycin A (AMA) was added to control mitochondrial integrity and background
activity, respectively. d The diagram shows statistical data from the experiment described in (c). e mRNA and f protein expression of
epithelial (E-cadherin (CDH1)) and mesenchymal (N-cadherin, (CDH2); vimentin, (VIM)) markers. g Phase contrast microscopy. Student’s t
test was used for statistical analysis. Data are shown as mean ± SEM for (a)–(d) and mean ± SD for (e). *p < 0.01
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supported by the normal response to oligomycin in
the presence of ADP. In summary, these data suggest
that initiation of the EMT program leads to attenu-
ation of SDH.
TWIST overexpression leads to reduced mitochondrial
biomass and changed organelle morphology
Based on the findings suggesting that EMT involves a
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Fig. 5 Induction of EMT in MCF10A cells overexpressing TWIST or SNAI2. The EMT-linked transcription factors TWIST and SNAI2 were
overexpressed in epithelial MCF10A cells. EMT was manifested by acquisition of mesenchymal traits. a Fluorescence microscopy for
detection of vimentin and E-cadherin, and cell morphology (using phalloidin to stain F-actin), in the parental cells (MCF10A/Par), and cells
overexpressing TWIST (MCF10A/TWIST) and SNAI2 (MCF10A/SNAI2). b Images (phase-contrast microscopy) showing spheroid formation
capacity. c Total cellular RNA versus DNA content (Hoechst 33258) in MCF10A/TWIST, compared to MCF10A/Par (flow cytometry). d
Protein expression of subunit SDHB and SDHC in MCF10A/Par and MCF10A/TWIST cells. e Mitochondrial respiration after overexpression of
EMT-linked transcription factors. Oxygen consumption rate (OCR) was measured after sequential additions of oligomycin (Oligo), CCCP,
rotenone (Rot), and antimycin A (AMA), in DMEM medium. f Extracted data from the experiment in (e), showing rates of basal and leak
(with oligomycin) respiration and respiratory capacity (uncoupled, with CCCP), in the MCF10A/TWIST and MCF10A/SNAI2 cells relative to
parental cells (CTR). g Leak respiration (with oligomycin) as the percentage of respiratory capacity (uncoupled, with CCCP), from the
experiment in (e). h SDH activity measured in restricted medium (MAS) after the supply of rotenone (Rot), succinate (Succ), ADP, and
permabilizing agent (PMP). Oligomycin (Oligo) and antimycin A (AMA) were then added to control mitochondrial integrity and
background activity. i The diagram shows statistical data from the experiment described in (h). Data are shown as mean ± SD (column
plots) or mean ± SEM (OCR traces). Student’s t test was used for statistical analysis. *p < 0.01
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through SDH downregulation, we investigated mito-
chondrial morphology in MCF10A/TWIST compared to
parental MCF10A cells using confocal microscopy and
quantitative 3D-image analysis. The mitochondria in
MCF10A cells were tubular and formed a compact and
continuous reticulum throughout the cytoplasm (Fig. 6a).
Mitochondria in MCF10A/TWIST cells were also tubu-
lar, but the structures were thinner and there was a frac-
tion of relatively small peripheral organelles dissociated
from the major mitochondrial assembly. Quantitative
analysis revealed that the number of organelles was sig-
nificantly higher in MCF10A/TWIST cells, compared to
parental cells (Fig. 6b). However, the total mitochondrial
volume was smaller (Fig. 6c), though the total mitochon-
drial tubule length was unchanged (Fig. 6d). Frequency
distribution analysis of single mitochondria showed
increased proportion of smaller organelles in the
MCF10A/TWIST cells (Fig. 6e). Consequently, small-
and medium-size mitochondria were found to constitute
a larger fraction of the total mitochondrial volume, com-
pared to epithelial MCF10A cells (Fig. 6f ). Increased
surface-to-volume ratio in MCF10A/TWIST mitochon-
dria further supported a change towards thinner tubular
structures compared to the parental phenotype (Fig. 6g).
Taken together, these imaging data show that EMT in































































































































































































































































































































































Fig. 6 Mitochondrial mass and morphology. Mitochondrial mass and morphology were compared in MCF10A (parental, epithelial) and MFC10A/
TWIST (mesenchymal) cells. a–g Confocal microscopy and quantitative image analysis of immune-stained mitochondria (TOM20 + ATPB). a Based
on confocal z-stacks, 3D-models of mitochondrial volume and filament structure were generated, as indicated from left to right in the two image
panels. b Mean number of mitochondria per cell (Nm). c Mean mitochondrial total volume per cell (Vm,cell). d Mean mitochondrial total tubule
length per cell (Lm,cell). e Size (volume) frequency distribution comparing mitochondria in MCF10A (parental) versus MCF10A/TWIST cells. f Volume
fraction analysis of mitochondrial subclasses (size). g Surface area (S.A.) to volume (Vm) regression analysis of individual mitochondria in MCF10A
(parental) and MCF10A/TWIST cells. The analysis comprised (parental/TWIST) 937/3643 mitochondria with total volume 9020/9554 μm3, in 30/61
cells (n). h–n Effects of TWIST overexpression on mtDNA and gene expression of mitochondrial proteins. h Amount of mtDNA in MCF10A/TWIST
relative to parental MCF10A. i Protein expression (WB) of TOM20. j Protein expression of PGC1α, including MCF10A/SNAI2 cells. k mRNA
expression of CPT1 and CYCS. l Protein expression (WB) of Drp1 (DMN1L) and Opa1. m mRNA expression of DMNL1 (Drp1), OPA1, MFN1, and
MFN2. n mRNA expression of PINK1 and PARK2. Student’s t test was used for statistical analysis. Data are shown as mean ± SD. *p < 0.01
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mitochondrial volume and a morphological change from
a compact mitochondrial reticulum to a more dispersed
and fragmented network of thinner tubules. Congruent
with reduced mitochondrial biomass, the MCF10A/
TWIST cells had reduced amounts of mitochondrial
DNA (mtDNA), TOM20 protein, the transcriptional co-
activator and key regulator of mitochondrial biogenesis
PGC1α, and mRNA levels of the mitochondrial proteins
carnitine palmitoyl transferase 1 (CPT1A) and cyto-
chrome c (CYCS) (Fig. 6h–k). Further supporting the
observed changes in mitochondrial dynamics, the mito-
chondrial fission-related Drp1 protein was found to be
upregulated, whereas the mitochondrial fusion protein
OPA1 was downregulated (Fig. 6l). Additional mRNA
expression analyses confirmed the upregulation of DMN1L
(DRP1) and indicated a trend for the downregulation of
OPA1 and MFN2 but not for MFN1, in the MCF10A/
TWIST cells compared to MCF10A/Par (Fig. 6m). Further,
we observed significantly higher PINK1 and PARK2 expres-
sion in MCF10A/TWIST cells (Fig. 6n). These data sup-
ports that EMT involves loss of mitochondrial biomass and
more fragmented organelle structure, consistent with re-
duced respiratory rates.
Potential links between SDH regulation and EMT activation
Finally, to investigate if the four SDH subunits may have
specific impacts on tumor metabolism, mitochondrial
dynamics and antioxidant systems related to EMT, we
performed correlation analysis including panels of marker
genes on the Affymetrix breast cancer cohort. A heat map
of the correlation coefficients (Spearman Rho) comparing
associations between specific genes of interest relative to
the SDH subunits and EMT markers is shown in Fig. 7
(the dataset is provided in Additional file 1: Table
S2). To clarify, since we aimed to identify potential
links between attenuated SDH and EMT activation,
we were looking for genes demonstrating an opposite
relationship towards SDH compared to EMT (i.e., Rho
value with opposite signs). In general, SDHA, SDHB, and
SDHC, demonstrated similar patterns of association with
this panel of genes, in contrast to SDHD that showed
some divergence compared to the other SDH subunits.
This association analysis did not suggest that expression
of the EMT315 signature, TWIST1, and SNAI2 was con-
sistently linked to HIF-1 target genes associated with gly-
colysis, apart from GLUT3 (Fig. 7a). The expression of
SDHA, SDAB, and SDHC tended to be positively associ-
ated with the metabolic HIF-1 target genes. Moreover,
western blot analysis of HIF-1α revealed no signs of in-
creased protein stabilization in MCF10A overexpressing
TWIST, or MCF7 SDHC/D+/+ and MCF7 SDHD+/− cells
(Additional file 2: Figure S4). Hence, although our findings
do not directly support that SDH suppression promotes a
HIF-1-regulated shift towards increased glycolysis in these
tumors, it still remains a possibility. HIF1-regulated genes
involved in EMT and invasion demonstrated a clear ten-
dency of inverse regulation relative to SDHA, SDHB, and
SDHC, while positively linked to EMT markers. Moreover,
the increasing expression of the SDH subunits was associ-
ated with increasing expression of markers of mitochon-
drial biomass (Fig. 7b). These markers generally showed
weak inverse relationships with EMT-linked gene expres-
sion. SDH subunit expression was also associated with
genes involved in both mitochondrial fission and fusion,
probably reflecting a parallel regulation of genes encoding
mitochondrial proteins. Further, a tendency of positive
association with autophagy genes such as BECN1 and
BNIP3 suggests that SDH downregulation is related to
modulation of autophagy, and an inverse association with
PARK2 may suggest that mitochondrial quality control is
activated under such conditions. Downregulation of SDH
subunits tended to be associated with downregulation of
antioxidant systems (i.e., positive associations), apart from
GPX2 and GPX5 showing inverse relationships with all
SDH subunits (Fig. 7c). The effects of such changes may
be complex, and these data do not reveal if potential
changes in tumor redox state due to reduced SDH subunit
expression may be associated with EMT. Although some
antioxidant enzymes appeared to linked to EMT, such as
GPX7 and GPX8, we did not find clear reciprocal relation-
ships with reduced expression of SDHC or the other SDH
subunits. Finally, analysis of three anticipated target genes
did not indicate that AMPK was coherently activated in
the context of SDH suppression but rather showed that
these genes were individually regulated, with CPT2 show-
ing a clear positive relationship with expression of SDHA,
SDHB, and SDHC (Fig. 7d).
Discussion
This study support that attenuation of SDH represents
an inherent element and driver mechanism of the EMT
program and especially points to SDHC as a contribut-
ing factor in the context of breast cancer. Through com-
prehensive cellular analyses, we characterized regulatory
and functional aspects of the relationship between EMT
and SDH, and further found the EMT program to in-
volve distinct changes in mitochondrial function and
morphology.
Based on previous reports suggesting that mitochon-
drial dysfunction and SDHB mutations promote EMT
[4, 37], we hypothesized that altered enzyme function of
SDH may be a determining factor and possibly an integral
part of EMT in human tumors, which could be linked to
an overarching shift in mitochondrial function and dy-
namics. Thorough analyses in breast cancer patient co-
horts revealed a relatively consistent inverse association
between EMT and reduced expression of the SDHC sub-
unit. Upon molecular and histological classification of the




Fig. 7 (See legend on next page.)
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breast cancer cohorts, we found that the relationship
between SDHC and EMT was stronger in the basal-like
subgroup compared to the non-basal-like subgroup.
Interestingly, when looking at overall survival, low
SDHC level was associated with a worse outcome in
basal-like breast carcinoma. This finding can imply that
suppressed activity of SDH-linked mitochondrial pathways
is associated with a worse prognosis in basal-like breast
carcinomas. As mitochondrial function is challenging to
assess in frozen and paraffin-embedded samples, there is an
urgent need for indicative markers reflecting mitochondrial
abnormalities. Our results suggest that SDHC expression
could serve as a potential prognostic marker to enable fur-
ther discrimination in the basal-like breast carcinoma sub-
group. Furthermore, upon histological classification of the
n = 204 breast cancer cohort, we found the inverse associ-
ation between SDHC and EMT to be more pronounced in
the ductal subgroup, compared to the lobular, but we did
not see an impact on the overall survival.
The relationship between SDHC and EMT was sup-
ported in subsequent studies revealing that EMT is in-
duced by CRISPR/Cas9-mediated knockdown of SDHC,
or SDH enzyme inhibition with malonate in respective
cell models. Under these conditions, EMT clearly in-
volved inhibition of SDH enzyme activity, as the ability
to utilize succinate as respiratory fuel was significantly
reduced. These findings extend the potential impact of
SDH attenuation on malignant mechanisms beyond the
role as tumor suppressor, as they suggest that transcrip-
tional suppression, not only genetic SDH defects, may
promote EMT.
Overexpression of EMT-linked transcription factors
(TWIST and SNAI2) caused SDH suppression, reduced
mitochondrial respiration, decreased amount of mitochon-
drial biomass (mtDNA and organelle volume), downregu-
lated mitochondrial biogenesis (including PGC1α), and
altered organelle structure. Noteworthy, context-dependent
changes of mitochondrial functional state are also often ac-
companied by accordant effects on organelle structure and
amount (i.e., mitochondrial dynamics) [38]. Our findings
provide mechanistic insights for previous reports elucidat-
ing context-dependent links between SDH inhibition, mito-
chondrial dysfunction, and EMT [4, 13, 22, 39]. The results
are also in agreement with findings suggesting that SNAI1
modulates cell metabolism by decreasing respiratory
activity via reduced SDH activity [40]. The EMT-linked
mechanisms involving reduced SDH activity may share
similarities with the action of other mitochondrial
tumor suppressors, such as fumarate dehydrogenase,
fumarate hydratase, and isocitrate dehydrogenase, as
well as OXPHOS defects that contribute to tumor de-
velopment [18, 41, 42]. According to our findings, it
can be speculated that an increased population of
smaller mitochondrial organelles may facilitate cellular
plasticity accompanying EMT and that this is associated
with processes of mitochondrial quality control, as sug-
gested by increased expression of PINK1 and PARK2. This
aspect is emphasized by findings in stem cells where mito-
chondrial quality is supported through asymmetric organ-
elle sorting during cell division [43] and the role of
mitochondrial dynamics during embryogenesis [44].
Interestingly, we found a clear relationship between
the cells’ ability to form spheroids, wound healing capacity,
and EMT state, related to downregulation of SDHC. This
observation constitutes a convincing example of how meta-
bolic rewiring may represent an integral part of cellular
plasticity. It may also incorporate established paradigms of
tumor metabolism where suppressed mitochondrial en-
ergetics supports biomolecule synthesis or antioxidant
defense [45]. Moreover, decreased proliferation and re-
duced dependency on mitochondrial respiration may
constitute a protective adaptation mediating tolerance
for a harsh microenvironment, including hypoxia, nu-
trient deprivation, and therapeutic pressures [46]. This
may, however, also open for targeted therapeutic strat-
egies. For instance, RCC tumors with SDHB mutations
has been shown to be highly dependent on an increased
influx of glucose, and glucose interfering drugs have
already been proposed as possible therapeutic strategies
[47]. Also, it has been shown that mutations in SDH
establishes a hypermethylated phenotype in PGL/PCC,
possible through the accumulation of succinate [48].
Interestingly, KRT19, one of the genes showing the
strongest evidence for epigenetic silencing in hyper-
methylated PGL/PCCs, is closely associated with EMT.
This may explain the particularly invasive phenotype of
SDHB-related tumors.
Gene expression analysis on the Affymetrix breast can-
cer cohort confirmed that downregulation of SDHA,
SDHB, SDHC, and/or SDHD is associated with increased
expression of EMT and invasion/migration markers and
pointed to specific genes that may link to accompanying
effects on energy metabolism, mitochondrial quality
control, and antioxidant systems to the induction of
EMT (Fig. 7). Although HIF-1 and AMPK may be in-
volved in these processes, it appears likely that some of
(See figure on previous page.)
Fig. 7 Gene expression analysis of potential links between SDH suppression and EMT activation. Gene expression (mRNA) analysis correlating
(Spearman) SDH subunits, EMT signature, TWIST1, and SNAI2 to panels of genes focusing on specific processes, based on data from the
Affymetrix breast cancer patient meta cohort (n = 3992). The heat map panels reflect the directions and strength (Rho value) of the associations.
The panels of genes included a HIF-1 targets, b factors involved in mitochondrial dynamic, c antioxidant enzymes, and d AMPK targets
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their anticipated target genes may also be regulated by
other mechanisms. Moreover, interactions of SDH and
other components of the respiratory chain may affect
EMT through effects on reactive oxygen species (ROS)
generation and scavenging. Such mechanisms likely de-
pend on cellular origin and phenotype, and probably the
state of EMT. Our investigations primarily focused on
long-term effects associated with EMT. Whether ROS
play a role in the induction of EMT, or transition be-
tween different states of EMT, would be an interesting
aspect for further studies, provided the metabolic links
revealed in the presented work.
As EMT is recognized as a driver mechanism of me-
tastasis, therapy resistance, and immune evasion, our
findings provide mechanistic support for further investi-
gations of mitochondrial features as potential thera-
peutic targets. To this end, mitochondria-targeted drugs
such as resveratrol and metformin have been reported to
inhibit EMT [49], and metformin has a preventive effect
on cancer incidence [50]. The presented findings point-
ing to SDH suppression as an integral part of the EMT
process may therefore open for new strategies to prevent
and treat malignancies.
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